X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (86) 86
humans (80) 80
oncology (61) 61
male (58) 58
cancer (44) 44
chemotherapy (43) 43
middle aged (37) 37
prostate cancer (33) 33
aged (31) 31
metastasis (31) 31
survival (27) 27
tumors (24) 24
female (22) 22
hematology, oncology and palliative medicine (22) 22
prostatic neoplasms, castration-resistant - drug therapy (20) 20
urology (20) 20
adult (19) 19
treatment outcome (19) 19
urology & nephrology (19) 19
care and treatment (17) 17
antineoplastic agents - therapeutic use (16) 16
neoplasm metastasis (16) 16
phenylthiohydantoin - analogs & derivatives (16) 16
disease-free survival (15) 15
docetaxel (15) 15
metastases (15) 15
patients (15) 15
prognosis (15) 15
survival analysis (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
immunotherapy (14) 14
therapy (14) 14
abiraterone acetate (13) 13
research (13) 13
antineoplastic agents - adverse effects (12) 12
bladder cancer (12) 12
cancer therapies (12) 12
cisplatin (12) 12
health aspects (12) 12
prostatic neoplasms, castration-resistant - pathology (12) 12
abridged index medicus (11) 11
drug therapy (11) 11
enzalutamide (11) 11
aged, 80 and over (10) 10
double-blind (10) 10
mutation (10) 10
phenylthiohydantoin - therapeutic use (10) 10
urothelial carcinoma (10) 10
analysis (9) 9
animals (9) 9
disease progression (9) 9
kaplan-meier estimate (9) 9
retrospective studies (9) 9
androgen receptor (8) 8
article (8) 8
double-blind method (8) 8
medical research (8) 8
patient outcomes (8) 8
prednisone (8) 8
prostatic neoplasms - drug therapy (8) 8
studies (8) 8
abiraterone (7) 7
antimitotic agents (7) 7
antineoplastic agents (7) 7
carcinoma (7) 7
carcinoma, renal cell - drug therapy (7) 7
cell lung-cancer (7) 7
kidney neoplasms - drug therapy (7) 7
life sciences (7) 7
lung neoplasms - drug therapy (7) 7
lung neoplasms - genetics (7) 7
lung-cancer (7) 7
medicine, general & internal (7) 7
mice (7) 7
pharmacology & pharmacy (7) 7
phenylthiohydantoin - adverse effects (7) 7
prostate-specific antigen - blood (7) 7
risk factors (7) 7
sorafenib (7) 7
time factors (7) 7
transitional-cell carcinoma (7) 7
antineoplastic agents - administration & dosage (6) 6
antineoplastic agents - pharmacology (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
apoptosis (6) 6
biopsy (6) 6
bladder-cancer (6) 6
cell line, tumor (6) 6
cisplatin - administration & dosage (6) 6
clinical trials (6) 6
clinical-trials (6) 6
diagnosis (6) 6
gene expression (6) 6
medical prognosis (6) 6
medicine, experimental (6) 6
melanoma (6) 6
men (6) 6
mitoxantrone (6) 6
nivolumab (6) 6
open-label (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10031, pp. 1909 - 1920
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10064, pp. 67 - 76
Journal Article
Journal Article
Science, ISSN 0036-8075, 01/2018, Volume 359, Issue 6371, pp. 91 - 97
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that... 
CELL LUNG-CANCER | MELANOMA | MICROENVIRONMENT | INTESTINAL MICROBIOTA | CYCLOPHOSPHAMIDE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | GENES | RESISTANCE | ANTITUMOR IMMUNITY | NIVOLUMAB | CD4 Antigens - immunology | Immunotherapy - methods | Humans | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Gastrointestinal Microbiome - genetics | Fecal Microbiota Transplantation | Anti-Bacterial Agents - therapeutic use | Feces - microbiology | Metagenome - genetics | Neoplasms - therapy | Animals | Receptors, CCR - immunology | Interleukin-12 - immunology | Receptors, CXCR3 - immunology | T-Lymphocytes - immunology | Mice | Gastrointestinal Microbiome - immunology | Verrucomicrobia - genetics | Verrucomicrobia - immunology | Care and treatment | Cell receptors | Microbiota (Symbiotic organisms) | Immunotherapy | Epithelial tumors | Physiological aspects | Health aspects | Methods | Apoptosis | PD-1 protein | Interleukin | Microbiomes | Transplantation | Lymphocytes T | Anticancer properties | Microbiota | Lymphocytes | Bacteria | Feces | Supplementation | Gnotobiotics | Kidneys | Melanoma | Dietary supplements | Interleukin 12 | Abundance | CXCR3 protein | Patients | CD4 antigen | Immune checkpoint | Antibiotics | Lungs | Flora | PD-L1 protein | Relative abundance | Antitumor activity | CCR9 protein | Tumors | Kidney transplantation | Cancer | Life Sciences
Journal Article
The Lancet, ISSN 0140-6736, 02/2018, Volume 391, Issue 10122, pp. 748 - 757
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 5, pp. 424 - 433
Journal Article
Nature, ISSN 0028-0836, 02/2018, Volume 554, Issue 7693, pp. 544 - 548
Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients... 
METASTATIC MELANOMA | CTLA-4 BLOCKADE | BLADDER-CANCER | THERAPY | LANDSCAPE | SUBTYPES | UROTHELIAL CARCINOMA | MULTIDISCIPLINARY SCIENCES | GENES | ADAPTIVE IMMUNE RESISTANCE | MPDL3280A | CD8-Positive T-Lymphocytes - cytology | Humans | Antibodies, Monoclonal - therapeutic use | Urothelium - pathology | Urologic Neoplasms - pathology | Neoplasm Metastasis | Urologic Neoplasms - drug therapy | Urologic Neoplasms - genetics | Immunotherapy | Antibodies - immunology | Antigens, Neoplasm - metabolism | Transforming Growth Factor beta - antagonists & inhibitors | Antigens, Neoplasm - analysis | Disease Models, Animal | Fibroblasts - metabolism | Antibodies - therapeutic use | Antigens, Neoplasm - immunology | Antibodies, Monoclonal - pharmacology | Treatment Outcome | B7-H1 Antigen - immunology | Urologic Neoplasms - immunology | Antibodies - pharmacology | Tumor Microenvironment - immunology | Collagen - metabolism | Phenotype | Animals | B7-H1 Antigen - antagonists & inhibitors | Signal Transduction - drug effects | Cell Cycle Checkpoints - drug effects | CD8-Positive T-Lymphocytes - drug effects | Urothelium - immunology | Mice | Mutation | CD8-Positive T-Lymphocytes - immunology | Urothelium - drug effects | Transforming Growth Factor beta - metabolism | Cohort Studies | Drug Resistance, Neoplasm - drug effects | PD-1 protein | CD8 antigen | Transforming growth factor-a | Antibodies | Parenchyma | Lymphocytes T | Metastasis | Immunity | Metastases | Genotype & phenotype | Signal transduction | Lymphocytes | Cell cycle | Fibroblasts | Growth factors | Urothelial cancer | Phenotypes | Cytokines | Melanoma | Blocking | Gene expression | Patients | Generalized linear models | Signaling | Stromal cells | Medical prognosis | Collagen | PD-L1 protein | Ligands | Determinants | Infiltration | Cancer | Tumors | Apoptosis | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article